Santhera Pharmaceuticals (Schweiz) AG
Records under this name other than patents Santhera Pharmaceuticals (Schweiz) AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 9 of 9 · Back to Santhera Pharmaceuticals (Schweiz) AG
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,791,289 | Color Adjustable Lamp Formerly held In force · High confidence | In force | High confidence | |
| US 10,716,762 | Transmucosal Administration System for a Pharmaceutical Drug Formerly held In force · High confidence | In force | High confidence | |
| US 10,806,703 | Transmucosal administration system for a pharmaceutical drug Held by another company In force · High confidence | In force | High confidence | |
| US 7,999,002 | Use of N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) or a pharmaceutically acceptable addition salt thereof for the prophylaxis and/or treatment of muscular dystrophy Lapsed on the fee record Ended Aug 16, 2023 · USPTO record | Lapsed on the fee record | Ended Aug 16, 2023 | USPTO record |
| US 7,977,388 | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of muscular dystrophies Lapsed on the fee record Ended Jul 12, 2023 · USPTO record | Lapsed on the fee record | Ended Jul 12, 2023 | USPTO record |
| US 7,078,379 | Treatment of congenital muscular dystrophies Term ended Term ended Feb 28, 2023 · USPTO record | Term ended | Term ended Feb 28, 2023 | USPTO record |
| US 7,875,648 | N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency Lapsed on the fee record Ended Jan 25, 2023 · USPTO record | Lapsed on the fee record | Ended Jan 25, 2023 | USPTO record |
| US 8,293,800 | Quinone Derivative 2,3-Dimethoxy-5-Methyl-6-(10-Hydroxydecyl)-1,4-Benzoquinone for the Treatment of Primary Progressive Multiple Sclerosis Formerly held Lapsed on the fee record Ended Oct 23, 2020 · High confidence | Lapsed on the fee record | Ended Oct 23, 2020 | High confidence |
| US 8,236,818 | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists Lapsed on the fee record Ended Aug 7, 2016 · USPTO record | Lapsed on the fee record | Ended Aug 7, 2016 | USPTO record |